Breast cancer - bevacizumab (in combination with a taxane) (TA214)
Fast, easy summary view of NICE guidance on 'advanced breast cancer'
NICE does not recommend bevacizumab in combination with a taxane as first treatment for people with metastatic breast cancer.
This guidance replaces terminated technology appraisal number 147 Bevacizumab in combination with paclitaxel for the first-line treatment of metastatic breast cancer, issued June 2008.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: advanced breast cancer
This page was last updated: 23 September 2013
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA214 Bevacizumab ar y cyd â taxane fel triniaeth gyntaf ar gyfer canser metastatig y fron: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.